These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10049445)

  • 41. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ASGE guideline on screening and surveillance of Barrett's esophagus.
    ; Qumseya B; Sultan S; Bain P; Jamil L; Jacobson B; Anandasabapathy S; Agrawal D; Buxbaum JL; Fishman DS; Gurudu SR; Jue TL; Kripalani S; Lee JK; Khashab MA; Naveed M; Thosani NC; Yang J; DeWitt J; Wani S;
    Gastrointest Endosc; 2019 Sep; 90(3):335-359.e2. PubMed ID: 31439127
    [No Abstract]   [Full Text] [Related]  

  • 43. Are screening and surveillance for Barrett's oesophagus really worthwhile?
    Sharma P; Sidorenko EI
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Barrett's esophagus: screening and prognosis].
    Mazzucchelli L; Wagner AC
    Ther Umsch; 2001 Mar; 58(3):158-64. PubMed ID: 11305154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy.
    Borovicka J; Fischer J; Neuweiler J; Netzer P; Gschossmann J; Ehmann T; Bauerfeind P; Dorta G; Zürcher U; Binek J; Meyenberger C
    Endoscopy; 2006 Sep; 38(9):867-72. PubMed ID: 16981102
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening strategies in gastroesophageal reflux disease: early identification of esophageal carcinoma.
    Shaheen NJ; Provenzale D
    Adv Intern Med; 2001; 47():137-57. PubMed ID: 11795073
    [No Abstract]   [Full Text] [Related]  

  • 47. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
    Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
    Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Barrett's esophagus carcinoma].
    Messmann H
    Praxis (Bern 1994); 2006 Jun; 95(25-26):1029-35. PubMed ID: 16836063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Are screening programs in Barrett esophagus meaningful?].
    Eckardt VF
    Zentralbl Chir; 2000; 125(5):424-30. PubMed ID: 10929626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New developments in the endoscopic surveillance of Barrett's oesophagus.
    Bergman JJ; Tytgat GN
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i38-42. PubMed ID: 15711007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of Barrett's esophagus: are we there yet?
    Gaddam S
    Dis Esophagus; 2018 Mar; 31(3):. PubMed ID: 29346553
    [No Abstract]   [Full Text] [Related]  

  • 52. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding cancer incidence in Barrett's esophagus: light at the end of the tunnel.
    Corley DA
    J Natl Cancer Inst; 2011 Jul; 103(13):994-5. PubMed ID: 21680911
    [No Abstract]   [Full Text] [Related]  

  • 54. Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database.
    von Rahden BH; Stein HJ; Weber A; Vieth M; Stolte M; Rösch T; Schmid RM; Sarbia M; Meining A
    Dis Esophagus; 2008; 21(8):685-9. PubMed ID: 18847456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening for Barrett's esophagus.
    DeVault KR
    Am Fam Physician; 2004 May; 69(9):2061-3. PubMed ID: 15152952
    [No Abstract]   [Full Text] [Related]  

  • 56. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Topic Complex VI: Barrett esophagus].
    Messmann H; Ell C; Fein M; Kiesslich R; Ortner M; Porschen R; Stolte M
    Z Gastroenterol; 2005 Feb; 43(2):184-90. PubMed ID: 15700212
    [No Abstract]   [Full Text] [Related]  

  • 58. [Screening for adenocarcinoma in Barrett's esophagus: yes or no, when and how?].
    Sostres C; Lacarta P; Lanas A
    Gastroenterol Hepatol; 2013 Oct; 36(8):520-6. PubMed ID: 23453559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Diagnosis of gastroesophageal reflux and Barrett esophagus].
    von Schrenck T
    Zentralbl Chir; 2000; 125(5):414-23. PubMed ID: 10929625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.